Who Paid My Doc
Rosa Negron Munoz
Child & Adolescent Psychiatry Lakeland, FL Medical Doctor
NPI 1578720165 CMS profile 891975
6700 S Florida Ave Ste 33, Lakeland, FL 33813
General payments
$38,757
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$686,896
Through program year 2025, Rosa Negron Munoz of Lakeland, FL is reported in the CMS Open Payments database as having received $38,757 across 416 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $686,896 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 98th percentile of Child & Adolescent Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $22,402 | 95 | |
| 2024 | General | $1,587 | 37 | |
| 2023 | General | $856 | 59 | |
| 2022 | General | $4,084 | 72 | |
| 2021 | General | $8,086 | 67 | |
| 2020 | General | $688 | 45 | |
| 2019 | General | $1,054 | 41 |
Beside peers
- Rosa Negron Munoz
- Child & Adolescent Psychiatry median
- Middle half of Child & Adolescent Psychiatry
- National median
In program year 2025, general payments to Rosa Negron Munoz were reported at $22,402. Among 1,601 Child & Adolescent Psychiatry profiles paid that year, the median was $132 and the middle half received between $41 and $474.
Show as a table
| Year | Rosa Negron Munoz | Child & Adolescent Psychiatry median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $1,054 | $129 | $42–$419 | $163 |
| 2020 | $688 | $81 | $28–$226 | $114 |
| 2021 | $8,086 | $115 | $31–$326 | $132 |
| 2022 | $4,084 | $124 | $40–$382 | $149 |
| 2023 | $856 | $130 | $45–$420 | $160 |
| 2024 | $1,587 | $141 | $42–$490 | $164 |
| 2025 | $22,402 | $132 | $41–$474 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Records
416 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Child & Adolescent Psychiatry in Florida
Craig Kunins
Child & Adolescent Psychiatry · Gulfport, FL
Elias Sarkis
Child & Adolescent Psychiatry · Gainesville, FL
Jeffrey Alvaro
Child & Adolescent Psychiatry · St Petersburg, FL
Sean Horan
Child & Adolescent Psychiatry · Miami, FL
Rachel Agustines
Child & Adolescent Psychiatry · Largo, FL
Carlos Borge
Child & Adolescent Psychiatry · Sarasota, FL
Related records
Child & Adolescent Psychiatry in Florida
Practitioners in the same specialty and state, ranked by reported value.
All Child & Adolescent Psychiatry
Everyone recorded under this specialty, nationwide.
Doctors in Florida
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.